Long-Acting Inhaled Bronchodilators:
The Mainstay of COPD Management

Peter J. Barnes, DM, DSc, FRCP, FMedSci, FRS
National Heart & Lung Institute, Imperial College, London, UK

ABSTRACT

Long-acting bronchodilators are the most effective treatments currently available for managing patients with COPD. Long-acting muscarinic antagonists and β₂-agonists are equally effective in producing bronchodilation, reducing symptoms, improving quality of life, and preventing exacerbations and are well tolerated. They probably work mainly by relaxing smooth muscle of peripheral airways to reduce gas trapping. Although both drug classes have non-bronchodilator effects that might be beneficial, this has not been clearly established in COPD patients. Remarkably, long-acting β₂-agonists and long-acting muscarinic antagonists have additive bronchodilator effects, although this has not always translated into greater clinical benefit. Nevertheless, long-acting β₂-agonist/long-acting muscarinic antagonist fixed-dose combinations are more effective than the single components and inhaled-corticosteroid/long-acting β₂-agonist combinations. Although there is some rationale for triple therapy with long-acting β₂-agonist/long-acting muscarinic antagonist/inhaled-corticosteroid, it remains to be shown that this would be more effective than long-acting β₂-agonist/long-acting muscarinic antagonist combinations, although may be indicated for COPD patients with frequent exacerbations and with overlapping features with asthma, including increased blood eosinophils. It is unlikely that new classes of bronchodilators will be developed for COPD and what is needed is effective and safe anti-inflammatory treatments.

Key words: Fixed dose combination inhaler. Long-acting β₂-agonist (LABA). Long-acting muscarinic antagonist (LAMA). Triple inhaler.
INTRODUCTION

Bronchodilators are the mainstay of current drug therapy for COPD, although the degree of bronchodilation is less than seen in asthma, typically about 5-10% improvement in forced expiratory volume in one second (FEV₁), although some patients show greater responses. However, bronchodilators may improve dyspnoea and exercise tolerance, despite little or no effect on spirometry, by reducing lung volumes by reducing hyperinflation (gas trapping). In addition, bronchodilators may improve mucociliary clearance. The choice of bronchodilator includes short- and long-acting β₂-agonists, anticholinergics (muscarinic receptor antagonists) and high doses of theophylline, and will partly be determined by patient preference and cost. The preferred bronchodilators are long-acting inhaled drugs such as long-acting β₂-agonists (LABA) or long-acting muscarinic antagonists (LAMA) and several are now available for COPD1 (Table 1).

MECHANISMS OF ACTION

It is likely that the major site of action of long-acting bronchodilators in COPD is small-airway smooth muscle, and that reducing cholinergic tone reduces airway closure on expiration, thereby reducing lung volumes and gas trapping, particularly on exertion (dynamic hyperinflation) and thus improving exercise tolerance2. Long-acting bronchodilators are more clinically effective than short-acting bronchodilators. The LAMA tiotropium bromide has a greater bronchodilator effect than ipratropium bromide four times daily, although the peak bronchodilator effect is similar. Ipratropium wears off completely before the next dose, whereas with tiotropium the bronchodilation is maintained over 24 hours3. Sustained bronchodilation is more effective in reducing symptoms and improving the quality of life in COPD patients. Similarly the once-daily LABA indacaterol is more effective than salmeterol and formoterol given twice daily4,5 and tiotropium once daily is more effective than salmeterol twice daily6, whereas once-daily indacaterol, tiotropium, and glycopyrrolate have equivalent bronchodilator effects7. An unexpected benefit of long-acting bronchodilators in COPD patients is the reduction in exacerbations, which was discovered when long-acting bronchodilators, either LABA or LAMA, were given over a period of 12 months or more. This was first demonstrated with tiotropium by chance3 and then confirmed in a study where reduction in exacerbations was the primary outcome8. The mechanisms for the reduction in exacerbations by long-acting bronchodilator therapy was thought to be due to the possible anti-inflammatory effects of these medications, but this has never been consistently documented with either LABA or LAMA in COPD patients1. A more likely explanation is that long-acting bronchodilators stabilize airways so that when exacerbations are induced by viral or bacterial infections, the airways are less likely to constrict.

LONG-ACTING MUSCARINIC ANTAGONISTS

Atropine is a naturally occurring compound that was introduced for the treatment of asthma but, because of side effects (particularly drying of secretions and central nervous system (CNS) effects), less soluble quaternary...
compounds (e.g. ipratropium bromide) were developed. Subsequently, tiotropium was discovered, which, although of similar chemical structure to ipratropium, was found to have an unexpectedly long duration of action. Anticholinergics are probably the most effective bronchodilators in the treatment of COPD, and vagal cholinergic tone appears to be the

**Table 1. Inhaled long-acting bronchodilators for COPD**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose (μg/puff)*</th>
<th>Formulation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LABA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol</td>
<td>6-12</td>
<td>MDI/DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>25</td>
<td>MDI/DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>75</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td>Vilaanterol</td>
<td>25</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td>Olodaterol</td>
<td>2.5</td>
<td>SMI</td>
<td>qd</td>
</tr>
<tr>
<td><strong>LAMA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiotropium</td>
<td>18</td>
<td>DPI/SMI</td>
<td>qd</td>
</tr>
<tr>
<td>Glycopyrrolate</td>
<td>50</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td>Umeclidinium</td>
<td>62.5</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td>Acildinium</td>
<td>400</td>
<td>DPI</td>
<td>bid</td>
</tr>
<tr>
<td><strong>LABA/LAMA FDC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indacaterol/glycopyrrolate (Ultibo®)</td>
<td>100/50</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td>Vilaanterol/umeclidinium (Anoro®)</td>
<td>22/55</td>
<td>DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Olodaterol/tiotropium (Spiotto®)</td>
<td>2.5/2.5</td>
<td>SMI</td>
<td>qd</td>
</tr>
<tr>
<td>Formoterol/glycopyrrolate (Bevespi®)</td>
<td>4.8/9</td>
<td>DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Formoterol/acildinium (Duaklir®)</td>
<td>12/340</td>
<td>DPI</td>
<td>bid</td>
</tr>
<tr>
<td><strong>ICS/LABA FDC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluticasone propionate/salmeterol (Seretide®/Advair®)</td>
<td>500/50</td>
<td>MDI/DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Budesonide/formoterol (Symbicort®, DuoResp®)</td>
<td>400/12</td>
<td>MDI/DPI</td>
<td>bid</td>
</tr>
<tr>
<td>BDP/formoterol (Foster®)</td>
<td>100/6</td>
<td>MDI/DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Fluticasone propionate/formoterol (Flutiform®)</td>
<td>400/12</td>
<td>MDI</td>
<td>bid</td>
</tr>
<tr>
<td>Fluticasone furoate/vilaanterol (Relvar®/Breo®)</td>
<td>200/25</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td><strong>ICS/LABA/LAMA FDC (Triple)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budesonide/formoterol/glycopyrrolate (BFG)®</td>
<td>?</td>
<td>MDI</td>
<td>bid</td>
</tr>
<tr>
<td>BDP/formoterol/glycopyrrolate®</td>
<td>100/6/12.5</td>
<td>MDI/DPI</td>
<td>bid</td>
</tr>
<tr>
<td>Fluticasone furoate/vilaanterol/umeclidinium</td>
<td>?</td>
<td>DPI</td>
<td>qd</td>
</tr>
<tr>
<td>Mometasone/indacaterol/glycopyrrolate (QVM149)</td>
<td>?</td>
<td>DPI</td>
<td>qd</td>
</tr>
</tbody>
</table>

*Dose of drug base leaving mouthpiece.
Currently available LAMA selectively target $M_3$ and $M_1$ muscarinic receptors in the airways. The major bronchodilator effect is through antagonising $M_3$ receptors, which are expressed on smooth muscle cells of all airways. Tiotropium has a prolonged inhibitory effect on cholinergic nerve-induced contraction of human airways in vitro and, after washing, persists for 15 hours compared with ipratropium, which persists for only 1-2 hours. Human airway smooth
muscle also expresses $M_2$ receptors, which inhibit cyclic adenosine monophosphate (AMP) accumulation and so antagonise the effects of $\beta_2$-agonists, but these are believed to play little functional role in regulating airway smooth muscle tone\textsuperscript{12}. The $M_2$ receptors on postganglionic nerves in the airways inhibit the release of acetylcholine and act as inhibitory auto-receptors, so that blocking $M_2$ receptors increases acetylcholine release and reduces the effect of competitive antagonism of $M_3$ receptors\textsuperscript{13}. The LAMA, such as tiotropium bromide and glycopyrrolate (glycopyrronium bromide), have a long duration of action on human $M_3$ receptors, but a much shorter duration of action on $M_2$ receptors, so that they have a kinetic selectivity\textsuperscript{9,14-16}. The $M_1$ receptors are expressed mainly on submucosal glands, where they mediate mucous secretion, and on parasympathetic ganglia, where they enhance ganglionic transmission and therefore reflex bronchoconstriction. Tiotropium and glycopyrrolate have a relatively long duration at these receptors and this may contribute to their favourable effects in COPD.

A small degree of resting bronchomotor tone is present because of tonic cholinergic nerve impulses, which release acetylcholine in the vicinity of airway smooth muscle, and cholinergic reflex bronchoconstriction may be initiated by irritants, cold air and stress. The LAMA reduce gas trapping by acting on small airways\textsuperscript{12} and thereby improve dyspnoea and symptoms with improvement in exercise tolerance\textsuperscript{17}. In peripheral airways there are few cholinergic nerves, which has suggested that peripheral cholinergic tone may be due to release of acetylcholine from extra-neuronal sources such as airway epithelial cells and even inflammatory cells\textsuperscript{18}. Cholinergic tone may be increased in COPD due to increased expression of muscarinic receptors\textsuperscript{19} as well as increased release of acetylcholine from non-neuronal sources.

Muscarinic receptors, including $M_3$ receptors, are expressed on several inflammatory cells, including macrophages, neutrophils, and T lymphocytes, suggesting that LAMA might have anti-inflammatory effects\textsuperscript{20}. For example, alveolar macrophages express $M_2$ and $M_3$ receptors and acetylcholine stimulates the release of the neutrophil chemotactic factor leukotriene (LT)-B\textsubscript{4}\textsuperscript{21}. In an animal model of COPD (cigarette smoke-exposed mice) tiotropium reduces neutrophilic inflammation, with concomitant reduction of LT$B_4$, IL-6, and KC (murine CXCL8)\textsuperscript{22}. Muscarinic receptors are also expressed on fibroblasts, and acetylcholine has a profibrotic effect that is blocked by tiotropium\textsuperscript{23-25}. The $M_3$ receptors on airway smooth muscle cells also stimulate proliferation, suggesting that LAMA may reduce structural remodelling of airways. Tiotropium also has an unexpected inhibitory effect on transient receptor potential V1 (TRPV1) channels that are involved in airway sensory nerve activation and this could explain its beneficial effect on cough\textsuperscript{26}. Interestingly, tiotropium also reduces rhinovirus infection of airway epithelial cells via an inhibitory effect on intercellular adhesion molecule 1 (ICAM-1), which acts as a receptor for this virus, so this could contribute to the reduction in infective exacerbations by LAMA\textsuperscript{27}. However, despite these interesting observations on the nonbronchodilator effects of tiotropium, there is so far no convincing evidence that LAMA have significant anti-inflammatory effects in COPD patients.
Clinical studies in COPD

Tiotropium bromide is a very effective once-daily bronchodilator in COPD patients that has minimal side effects at the normally recommended doses\(^{28}\). It is given by a dry powder inhaler (Handihaler\(^{20}\)) or as a soft mist inhaler (Respimat\(^{20}\)) and gives bronchodilation that carries over to the next day, thus providing persistent bronchodilation\(^3\). This results in significantly better improvement in the quality of life (St George’s Respiratory Questionnaire) than ipratropium bromide given four times daily. Indeed studies with methacholine challenge in asthma patients suggest that its duration of action may be up to 72 hours\(^{29}\). Unexpectedly, tiotropium also reduced exacerbations and hospitalisations in long-term studies\(^8\), which was confirmed in the large UPLIFT study over four years compared to placebo, even when added to other treatments, including LABA and inhaled corticosteroids (ICS)\(^{30}\). Overall, tiotropium does not reduce disease progression, but in patients with moderate disease (GOLD2) and in early disease, there is a small reduction in annual decline of FEV\(_1\) and forced vital capacity\(^{31,32}\).

Several other LAMA have now been developed. Glycopyrrollate is an old drug used systemically to dry airway secretions before anaesthesia and first shown to be a long-acting bronchodilator of similar duration to tiotropium in 2005\(^{33}\). Glycopyrrollate is usually given once daily and has a very similar profile to tiotropium in COPD patients\(^{34-36}\). However, in low doses, glycopyrrollate should be given twice daily\(^{37}\). Umeclidinimum is another once-daily LAMA, very similar in profile to tiotropium and glycopyrrollate\(^{38}\). Aclidinimum is also a LAMA, but appears to have a shorter duration than tiotropium so is given twice daily\(^{39,40}\). However, aclidinimum has a faster onset of action than other LAMA, although this is of no clinical relevance as LAMA are given as regular maintenance therapy rather than for symptom relief as required.

Side effects

All LAMA have a similar safety profile and are well tolerated in elderly patients with COPD. Dry mouth is seen in approximately 10% of patients and is due to reduced salivary flow, probably a local effect due to M\(_1\) receptor inhibition, but this often disappears with continued use. There are occasional reports of urinary retention and there is a theoretical risk of glaucoma. Some studies were interpreted as showing increased cardiovascular mortality with tiotropium, particularly when given by soft mist inhaler (Respimat\(^{20}\))\(^{41}\). However, cardiovascular mortality was significantly reduced in the UPLIFT study using dry powder inhaler, and was not increased in a large safety study using Respimat\(^{30,42}\).

LONG-ACTING \(\beta_2\)-AGONISTS

Short-acting \(\beta_2\)-agonists are used mainly for symptom relief as required, but may be used four times a day on a regular basis. However, LABA are preferred as they give better control of symptoms and are used as a maintenance therapy.

Mode of action

The \(\beta_2\)-agonists have several potential beneficial effects on the airways in COPD\(^{13}\). These
drugs act directly on $\beta_2$-adrenoceptors on airway smooth muscle, causing a relaxation in large and small airways. They act as functional antagonists and reverse bronchoconstriction, irrespective of cause. They also have several non-bronchodilator effects that may potentially contribute to their clinical benefit in COPD (Fig. 2). Experimentally, they reduce plasma exudation and cholinergic reflexes. They also increase mucociliary clearance (when it is reduced). Evidence suggests that $\beta_2$-agonists may reduce adherence of bacteria to airway epithelial cells and this may contribute to their reduction of infective exacerbations.\textsuperscript{44} There is some evidence that $\beta_2$-agonists may increase the ventilatory drive to hypercapnia (but not to hypoxia). It is still uncertain whether LABA have long-term anti-inflammatory effects in COPD, and any anti-inflammatory effects on inflammatory cells are usually rapidly tachyphylactic. However, formoterol significantly reduces sputum neutrophils in patients with neutrophilic asthma by inhibiting the release of the neutrophil chemoattractant CXCL8 from airway epithelial cells.\textsuperscript{45} This anti-neutrophil effect has not yet been demonstrated in COPD patients, however.

**Clinical use**

Salmeterol and formoterol give bronchodilation and protection against bronchoconstriction for over 12 hours. Nebulised formoterol, including the active enantiomer (arformoterol) is also effective in COPD, but it is only...
available in the USA\textsuperscript{46,47}. Indacaterol and olodaterol are once-daily LABA that are now approved for use in COPD and have a similar efficacy and safety profile\textsuperscript{48,49}. Vilanterol is another once-daily LABA, but not yet approved as monotherapy. Once-daily LABA are more effective than twice-daily LABA, supporting the view that maintained bronchodilation is beneficial. LABA improve symptoms, quality of life, and exercise performance and reduce air trapping through relaxant effects on small airways\textsuperscript{50}. In long-term studies they reduce exacerbations and may reduce mortality\textsuperscript{51,52}. They have a similar efficacy to LAMA, although once-daily tiotropium is more effective than twice-daily salmeterol in preventing exacerbations and hospitalisation\textsuperscript{6}. However, as discussed above, once-daily tiotropium and glycopyrrolate are similar to once-daily indacaterol\textsuperscript{7}.

**Side effects**

Side effects are not usually a problem with LABA in COPD, even with hypoxia and cardiovascular comorbidity\textsuperscript{50}. A large study recently showed that even in COPD patients with cardiovascular risk, there was no increase in cardiovascular events after treatment with once-daily vilanterol\textsuperscript{54}. Muscle tremor (direct effect on skeletal muscle $\beta_2$-receptors) is more common in elderly patients, but tends to disappear through development of tolerance with time. Tachycardia (direct effect on atrial $\beta_2$-receptors and reflex effect from increased peripheral vasodilatation via $\beta_2$-receptors) may cause palpitations, but tolerance usually develops. Hypokalaemia is a direct effect on skeletal muscle uptake of potassium ions via $\beta_2$-receptors, but is usually a small effect. Hypoxaemia due to increased ventilation/perfusion (V/Q) mismatch due to pulmonary vasodilatation is not a problem with chronic treatment.

**LONG-ACTING $\beta_2$-AGONIST/ LONG-ACTING MUSCARINIC ANTAGONIST FIXED-DOSE COMBINATION INHALERS**

The bronchodilator effects of LABA and LAMA appear to be additive, at least as measured by FEV\textsubscript{1}. This was demonstrated initially with an additive bronchodilator effect of either formoterol or salmeterol twice daily added to tiotropium once daily\textsuperscript{55,56}. Adding indacaterol in patients also treated with tiotropium also shows an add-on bronchodilator effect\textsuperscript{57}. In one study, a maximally effective bronchodilator dose of indacaterol was given and, since LABA inhibit all bronchoconstrictor mechanisms, including cholinergic tone, no further bronchodilation should be possible\textsuperscript{58}. However, the addition of glycopyrrolate in combination with indacaterol (Ultibro\textsuperscript{®}) almost doubled the bronchodilator response. It is possible that this is achieved through some effect in addition to reduction in cholinergic tone, such as an effect on mucus hypersecretion, although this is unlikely as the additive effect is seen immediately. Another possibility is that there is some cross-talk between cholinergic and adrenergic signalling pathways in airway smooth muscle cells. Cholinergic tone is mediated via an effect of acetylcholine on M\textsubscript{3} receptors on airway smooth muscle cells, which are coupled to phospholipase C$\beta$ (PLC$\beta$), which generates the second messenger inositol 3,4,5 trisphosphate (IP\textsubscript{3}) that is responsible for the release of calcium ions from internal stored, resulting in muscle contraction. The
PLCβ also generates another second messenger, diacylglycerol, which activates membrane-bound protein kinase C (PKC), which is able to phosphorylate both \(\beta_2\)-receptors and the stimulatory G-protein (\(G_s\)), resulting in uncoupling of \(\beta_2\)-receptors with reduction in cyclic AMP, which is a braking mechanism for \(\beta_2\)-agonist induced bronchodilation\(^{59}\). By adding an \(M_3\) antagonist, this braking effect would be relieved, thus giving a larger bronchodilator effect of the \(\beta_2\)-agonist (Fig. 3).

The additive bronchodilator effect is also seen after chronic dosing, with a reduction in symptoms and improved quality of life\(^{7,57,60,61}\), but far less than additive effects in preventing exacerbations\(^{60}\). Recently, several other LABA/LAMA combination inhalers have been developed, including once-daily vilanterol/umeclidinium (Anoro) and olodaterol/tiotropium (Spiolto), and twice-daily formoterol/glycopyrrolate (Bevespi) and formoterol/acellularinum (Duaklir)\(^{62-64}\). The LABA/LAMA fixed-dose combinations have similar effects in terms...
of efficacy and prevention of exacerbations, as shown by a recent network meta-analysis, in the absence of direct head-to-head comparisons. It is likely that LABA/LAMA combination inhalers will become first-line therapy, especially as they appear more effective in reducing symptoms than an ICS/LABA combination. Indacaterol/glycopyrrolate once daily is more effective in preventing exacerbations than twice-daily fluticasone propionate/salmeterol, which has been widely used in the initial treatment of COPD in conflict with guideline recommendations. Side effects do not appear to be a problem with LABA/LAMA combinations as the two classes of drug have different off target effects.

**INHALED CORTICOSTEROID/LONG-ACTING ß2-AGONIST FIXED-DOSE COMBINATION INHALERS**

Several fixed-dose ICS/LABA combination inhalers have been used in COPD patients, including twice-daily fluticasone propionate/salmeterol (Seretide®, Advair®), budesonide/formoterol (Symbicort®), and beclomethasone dipropionate/formoterol (Foster®), and once-daily fluticasone furoate/vilanterol (Relvar®, Breo®) and these combinations are more convenient and may improve adherence. Several studies have demonstrated a benefit of combination inhalers containing a corticosteroid and a LABA in COPD patients. However, most of the benefit seems to be provided by the LABA component. Patients with severe COPD at risk of exacerbations could be withdrawn from ICS therapy without risk of increased exacerbations, suggesting that ICS were not providing any additional value. In the Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM) study, ICS were slowly withdrawn from patients with a history of exacerbations in the previous year without evidence of increased exacerbations, although there was a small fall in FEV₁. In some patients it may be possible to gradually decrease the ICS because the incidence of subsequent exacerbations of patients continued on double bronchodilator therapy is not increased. However, patients with poor lung function should be monitored because some may have significant decrease in lung function that may signal a benefit from the ICS therapy.

Any superiority of combination inhalers over LABA alone in reducing exacerbations may be counteracted by the higher risk of side effects due to the corticosteroid component. The ICS/LABA combination inhalers improve symptoms and reduce exacerbations with a reduction in all-cause mortality, although this does not quite reach statistical significance. The reduction in exacerbation between twice-daily fluticasone/salmeterol is similar to that seen with tiotropium. The ICS/LABA combination inhalers may be useful when patients with FEV₁ < 50% predicted and with frequent exacerbations (≥2/year) who are already on tiotropium need further treatment. The once-daily ICS/LABA combination inhaler (fluticasone furoate/vilanterol, Relvar®) has been approved for use in COPD, although there appears little difference in comparison with vilanterol alone and its effects are similar to twice-daily fluticasone propionate/salmeterol with a similar side effect profile (including increased risk of pneumonia). However, the fluticasone furoate/vilanterol combination is more effective in reducing exacerbations than...
vilanterol alone if blood eosinophils are ≥ 2% and particularly > 6%.

Recently, there has been considerable interest in predicting which COPD patients may benefit from ICS added to LABA. There is some evidence that increased blood eosinophils may predict a better clinical response to ICS/LABA in terms of reduced exacerbations. A post hoc analysis of a study that compared fluticasone furoate/vilanterol with vilanterol alone showed a greater effect of the combination in patients with blood eosinophils ≥ 2% (200/µl) than those with < 2%, and the difference was greater the higher the blood eosinophils76. However, the absolute number of exacerbations on the combination was unchanged at differing blood eosinophil counts, suggesting that vilanterol may even increase exacerbations. In addition, there were no differences in lung function of symptoms between these treatments at different eosinophil cut-off points. This was supported by three other studies that compared ICS/LABA with tiotropium77, but not by a further analysis of the fluticasone furoate/vilanterol versus vilanterol data78. However, a more recent study showed that blood eosinophils did not predict any better responses to fluticasone/salmeterol compared to indacaterol/glycopyrrolate69. When ICS are withdrawn, only patients with blood eosinophils ≥ 4% appear to be at greater risk of increased exacerbations79. The importance of blood eosinophils as a marker is uncertain and there may be little relationship to sputum or lung eosinophils.

TRIPLE INHALERS

Addition of a LAMA to an ICS/LABA inhaler appears to give further improvement in lung function and reduction in exacerbations80-84. This has suggested that a triple fixed-dose combination of ICS/LABA/LAMA may be useful and several triple combinations are now in development for COPD86,87. Many patients with COPD now end up on triple therapy since their symptoms persist whatever treatment is given. The introduction of triple fixed-dose combination inhalers may therefore be popular, although relatively few patients with COPD benefit from ICS therapy. If patients are started on a LAMA and then proceed to a fixed-dose LABA/LAMA combination, it might be better to then switch to a triple inhaler if there is indication (frequent exacerbations, high blood eosinophil count, clinical features of asthma-COPD overlap) rather than adding an ICS alone as this is unlikely to be used by patients consistently. Triple inhalers may be more expensive, may lead to long-term steroid side effects, and may be difficult to develop because of physical and chemical interactions between the three components. It will be necessary to show that the triple inhalers are significantly more effective than LABA/LAMA combinations and this is likely to be a difficult barrier to overcome.

CONCLUSIONS

There is no doubt that long-acting bronchodilators are now the mainstay of treatment for COPD patients, providing clinically meaningful improvements in symptoms, quality of life and prevention of exacerbations. There do not appear to be significant differences between individual LAMA and LABA, although a longer duration of action (once daily) is preferable in terms of stabilizing airway function. What is still unclear is whether some patients
respond better to LAMA and others to LABA, and if so, how this can be predicted. What is also uncertain is whether there are any non-bronchodilator effects of these drugs that may be clinically relevant, such as reduced mucus secretion, increased mucociliary clearance, or anti-inflammatory or neural inhibitory effects, and this deserves further study. The value of adding an ICS to LABA/LAMA combinations is not yet clear, but some patients, such as those with increased eosinophils and asthma-COPD overlap features, may benefit from triple therapy. More research is needed to understand whether bronchodilation may be even greater with new classes of bronchodilator. It has proved very difficult to identify new classes of bronchodilator that are close to the cost-benefit provided by LABA and LAMA. Bitter taste receptor (TAS2R) agonists have been shown to relax human airways, but are less effective than β2-agonists. Phosphodiesterase-3 inhibition may provide bronchodilation, but has been linked to cardiovascular side effects. What is most needed in COPD are new anti-inflammatory therapies that are effective and safe, but this has proved to be a major challenge, and a better understanding of the underlying disease proves the need to identify new promising therapeutic targets.

REFERENCES


82. Rojas-Reyes MX, Garcia Morales OM, Dennis RJ, Karner C. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;CD008532.


